Sort
48,018 grants matching “immunotherapy”
Multi-color laser particles for high-throughput pooled analysis
$478,694Seok H Yun · Massachusetts General Hospital · R01 · FY2025 · EB
Targeted Gene Delivery and Human Dendritic Cell Maturation Through a Novel Hybrid Biological-Biomaterial Vector System
$478,685Blaine A. Pfeifer · State University Of New York At Buffalo · R01 · FY2025 · CA
Understanding and Overcoming Resistance to BRAF/MEK Kinase Inhibitors in Melanoma
$478,669Arjun Raj · University Of Pennsylvania · R01 · FY2024 · CA
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
$478,551Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA
Targeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to Immunotherapy
$478,551Roberta Zappasodi · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Modulation of Inflammatory Responses by Helminth Glycans
$478,549Richard D Cummings · Emory University · R01 · FY2014 · AI
ISS-ODN activation of tonsillar APCs to augment immunity
$478,538Melissa J Robbiani · Population Council · R01 · FY2008 · DE
Biological and clinical significance of spatial immune heterogenenity in non-small cell lung cancer
$478,532Kurt A Schalper · Yale University · R21 · FY2025 · CA
Regulation of encephalitogenic T cells by CRAC channels
$478,517Stefan Feske · New York University School Of Medicine · R01 · FY2019 · AI
Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB
$478,506Jessica L Reynolds · State University Of New York At Buffalo · R01 · FY2019 · AI
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma
$478,486Keiran Smalley · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2023 · CA
Mechanistic Core
$478,416Lloyd F Mayer · Icahn School Of Medicine At Mount Sinai · U19 · FY2010 · AI
EASTERN COOPERATIVE ONCOLOGY GROUP
$478,386University Of Rochester · U10 · FY2000 · CA
Clinical Investigation of Epigenetic Therapy
$478,381John C Byrd · Ohio State University · P01 · FY2007 · CA
Targeting through Selective Cell Labeling
$478,351Jianjun Cheng · University Of Illinois At Urbana-Champaign · R01 · FY2018 · EB
Mechanisms of uveal melanoma dormancy and targeted therapy tolerance
$478,344Andrew E Aplin · Thomas Jefferson University · R01 · FY2021 · CA
Project 4: Therapeutic Targeting of Replication Stress Vulnerabilities in Small Cell Lung Cancer
$478,337Lauren Averett Byers · Ut Southwestern Medical Center · P50 · FY2024 · CA
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
$478,329Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2022 · CA
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
$478,329Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2023 · CA
INNATE IMMUNE THERAPIES IN B CELL MALIGNANCIES
$478,215John C Byrd · Ohio State University · P01 · FY2008 · CA
AHR-mediated immunosuppression in glioblastoma
$478,176Francisco J. Quintana · Brigham And Women'S Hospital · R01 · FY2021 · ES
Mammalian and Plant-derived Antibody-based Therapies against Sudan Ebolavirus
$478,167John M Dye · Geneva Foundation · R01 · FY2015 · AI
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$478,123Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2022 · DK
Dissecting the NRG4 hormonal checkpoint in metabolic liver disease
$478,123Jiandie D Lin · University Of Michigan At Ann Arbor · R01 · FY2023 · DK
Senescence as a Therapeutic Endpoint
$478,108Meenhard Herlyn · Wistar Institute · P01 · FY2015 · CA